The importance of maximal TURBT in trimodality therapy for muscle-invasive bladder cancer (MIBC).

IF 1 4区医学 Q4 ONCOLOGY

Bladder Cancer Pub Date : 2025-06-12 eCollection Date: 2025-04-01 DOI:10.1177/23523735251346569

Chris Ho-Ming Wong, Ivan Ching-Ho Ko, David Ka-Wai Leung, Brian Siu, Steffi Kar-Kei Yuen, Jeremy Yuen-Chun Teoh

引用次数: 0

Abstract

Trimodality therapy (TMT), consisting of maximal transurethral resection of bladder tumor (TURBT) followed by concurrent chemoradiotherapy, has emerged as a bladder-sparing alternative to radical cystectomy for select patients with muscle-invasive bladder cancer (MIBC). While each component of TMT plays a critical role, maximal TURBT is foundational to its success. This review examines the importance of maximal TURBT in optimizing oncological outcomes in TMT, discusses its technical nuances, and explores the evidence supporting its role in achieving durable local control and improving survival outcomes in MIBC.

查看原文本刊更多论文

最大TURBT在肌侵性膀胱癌三段式治疗中的重要性。

三联疗法（TMT），由最大经尿道膀胱肿瘤切除术（turt）和同步放化疗组成，已成为选择性肌肉浸润性膀胱癌（MIBC）患者根治性膀胱切除术的膀胱保留替代方案。虽然TMT的每个组成部分都起着至关重要的作用，但最大的turt是其成功的基础。本综述探讨了最大turt在优化TMT肿瘤预后中的重要性，讨论了其技术上的细微差别，并探讨了支持其在实现持久局部控制和改善MIBC生存结果中的作用的证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bladder Cancer Medicine-Urology

CiteScore

1.60

自引率

0.00%

发文量

期刊介绍： Bladder Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the bladder and upper urinary tract. The journal publishes research reports, reviews, short communications, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that expedites our fundamental understanding and improves treatment of tumors of the bladder and upper urinary tract.